BACKGROUND: The safety and feasibility of administering S-1 adjuvant chemotherapy for gastric cancer has not been fully evaluated in elderly patients. METHODS: This retrospective study selected patients who underwent curative D2 surgery for gastric cancer, were diagnosed with stage II or III disease, and received adjuvant S-1 at our institution. Patients were categorized into two groups; non-elderly patients (age <70 years: group A) and elderly patients (age ≥70 years: group B). The toxicity and S-1 continuation rates in the two groups were compared. RESULTS: A total of 75 patients were evaluated in the study. There were no grade 4 toxicities. The incidences of grade 3 hematological and non-hematological toxicities were <5% in both groups, and the differences were not significant. The continuation rate at 6 months was 69% in group A and 70% in group B, and this difference was also not significant. CONCLUSIONS: These results suggest that S-1 adjuvant chemotherapy for gastric cancer is safe and feasible, regardless of the age of the patient; especially for elderly patients who could be candidates for clinical trials.
BACKGROUND: The safety and feasibility of administering S-1 adjuvant chemotherapy for gastric cancer has not been fully evaluated in elderly patients. METHODS: This retrospective study selected patients who underwent curative D2 surgery for gastric cancer, were diagnosed with stage II or III disease, and received adjuvant S-1 at our institution. Patients were categorized into two groups; non-elderly patients (age <70 years: group A) and elderly patients (age ≥70 years: group B). The toxicity and S-1 continuation rates in the two groups were compared. RESULTS: A total of 75 patients were evaluated in the study. There were no grade 4 toxicities. The incidences of grade 3 hematological and non-hematological toxicities were <5% in both groups, and the differences were not significant. The continuation rate at 6 months was 69% in group A and 70% in group B, and this difference was also not significant. CONCLUSIONS: These results suggest that S-1 adjuvant chemotherapy for gastric cancer is safe and feasible, regardless of the age of the patient; especially for elderly patients who could be candidates for clinical trials.
Authors: T Shirasaka; Y Shimamato; H Ohshimo; M Yamaguchi; T Kato; K Yonekura; M Fukushima Journal: Anticancer Drugs Date: 1996-07 Impact factor: 2.248
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun Journal: CA Cancer J Clin Date: 2006 Mar-Apr Impact factor: 508.702
Authors: Natalie Liu; Daniela Molena; Miloslawa Stem; Amanda L Blackford; David B Sewell; Anne O Lidor Journal: J Gastrointest Surg Date: 2018-02-05 Impact factor: 3.452
Authors: Natalie Liu; Yiwei Xu; Amir A Rahnemai-Azar; Daniel E Abbott; Sharon M Weber; Anne O Lidor Journal: J Gastrointest Surg Date: 2019-12-02 Impact factor: 3.452